SLC5A2 and chronic kidney disease: EMPA-KIDNEY demonstrated the clear benefits of SGLT2 inhibition on kidney disease progression in a wide range of patients with CKD at risk of progression, including about a one-third reduction in the risk of needing to start kidney replacement therapy.11 This large EMPA-KIDNEY substudy benefits from its sample size, long duration, systematic measurements, and randomized double-blind design.